Vioxx Information
What's inside Vioxx
Vioxx Active Ingredients: rofecoxib, details.| Vioxx Dosages & Strengths | ||||
|---|---|---|---|---|
| Strength | Format | Route | Strength | Class |
| Vioxx 12.5 mg | tablet | oral | 1.0 each | OTC |
| Vioxx 25 mg | tablet | oral | 1.0 each | OTC |
| Vioxx 50 mg | tablet | oral | 1.0 each | OTC |
| Vioxx 25 mg/5 mL | suspension | oral | 5.0 milliliter(s) | OTC |
| Vioxx 12.5 mg/5 mL | suspension | oral | 5.0 milliliter(s) | OTC |
Recent Vioxx Side Effects
Posted by thrillme over 3 years ago
I experienced complete Loss of hearing in my left ear for 24 hours & stopped taking the Vioxx at the first sign of a problem....
Posted by cool_ie01 over 4 years ago
After I had used vioxx for a while i started experiecing tight chest pains, Then a while later on in the month's I was diagno...
Posted by rvrlkedeb over 5 years ago
I have been taking Vioxx 50mg daily for 10 years now. I have arthritis in my hands and hips and one knee, due to an accident....
Vioxx in the News
Merck Nailing Down Vioxx Settlement - Wall Street Journal
Merck has taken a big step toward doling out $4.85 billion to settle lots and lots of Vioxx lawsuits. The drug maker said this morning that it’s confident ...
Mon Mar 03 10:10:54 -0500 2008
93% have filed for Vioxx settlement, Merck says - Bizjournals.com
Inc. said Monday it continues to make progress on its $4.85 billion Vioxx settlement agreement. According to the pharmaceutical company, more than 44000 of ...
Mon Mar 03 10:23:42 -0500 2008
Merck says thousands file for Vioxx payments - Reuters India
CHICAGO (Reuters) - Merck & Co on Monday said it has moved closer to resolving thousands of claims arising from its 2004 withdrawal of arthritis pill Vioxx, ...
Mon Mar 03 15:33:57 -0500 2008
Vioxx Chemical Information
rofecoxib - A synthetic, nonsteroidal derivative of phenyl-furanone with antiinflammatory, antipyretic and analgesic properties and potential antineoplastic properties. Rofecoxib binds to and inhibits the enzyme cyclooxygenase-2 (COX-2), resulting in an inhibition of the conversion of arachidonic acid to prostaglandins. COX-related metabolic pathways may represent key regulators of cell proliferation and neo-angiogenesis. Some epithelial tumor cell types overexpress pro-angiogenic COX-2. (NCI04)
Vioxx RSS Feed
